02:03 , Jun 15, 2019 |  BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day Congressional...
23:45 , Jun 14, 2019 |  BioCentury  |  Politics, Policy & Law

No more crickets: The biopharma industry must speak out against the Trump administration’s fetal tissue ban

When President Donald Trump considered a range of options about regulating the use of fetal tissue in medical research, he made a simple political calculation. A ban would solidify support from religious anti-abortion advocates, while...
21:57 , Jun 10, 2019 |  BC Extra  |  Politics & Policy

Stakeholders back Medicare Part D out-of-pocket cap, call for additional changes to lower patient costs

The biopharmaceutical industry, patient groups, PBMs and other stakeholders have endorsed proposals to cap out-of-pocket drug costs for Medicare Part D beneficiaries in comments submitted to the House Ways and Means and Energy and Commerce...
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
19:40 , Jun 4, 2019 |  BC Extra  |  Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
21:36 , Jun 3, 2019 |  BC Extra  |  Company News

Management tracks: Zai, Jazz, PTC, BIO and more

Cancer company Zai Lab Ltd. (NASDAQ:ZLAB) hired Valeria Fantin as its first CSO. She was CSO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Cancer and neurology company Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hired Robert Iannone...
00:37 , May 10, 2019 |  BC Innovations  |  Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

Congress has taken the first step towards fixing a key problem with patent policy that has crippled the diagnostics industry and disrupted development of other life science inventions, but its proposed solution falls short for...
00:31 , May 10, 2019 |  BC Innovations  |  Product Development

The time is now: novel partnerships and funding models for accelerating science to the marketplace

We are in a golden age of biopharmaceutical development, enabled by the convergence of technology and science. But much of the gold is left unmined because mechanisms are not deployed to develop all compounds that...
01:35 , Mar 16, 2019 |  BioCentury  |  Politics, Policy & Law

Lukewarm response to cold war on international pricing index

PhRMA and BIO have gone to war against the Trump administration’s proposal to reference some Medicare Part B drug prices to a basket of prices paid in other countries, but they haven’t found many allies...
22:30 , Mar 5, 2019 |  BC Extra  |  Politics & Policy

PhRMA, BIO on board with NIH's HEAL committee

NIH said it partnered with PhRMA and BIO to form a committee to help guide its Helping to End Addiction Long-term Initiative to address pain and addiction. Industry, academics and patients will be represented on...